Comparative Pharmacology
Head-to-head clinical analysis: FLAGYL versus METRONIDAZOLE HYDROCHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FLAGYL versus METRONIDAZOLE HYDROCHLORIDE.
FLAGYL vs METRONIDAZOLE HYDROCHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Metronidazole, a nitroimidazole antibiotic, enters bacterial cells and is reduced to cytotoxic intermediates that damage DNA and inhibit nucleic acid synthesis, leading to cell death. It is active against anaerobic bacteria and protozoa.
Upon anaerobic reduction of the nitro group, forms toxic intermediates that damage bacterial DNA and inhibit nucleic acid synthesis.
Metronidazole 500 mg intravenously every 8 hours or 500 mg orally every 8 hours.
Intravenous: 500 mg every 6 hours or 500 mg every 8 hours. Typical adult dose: 500 mg IV every 6 hours.
None Documented
None Documented
Terminal elimination half-life: 6-8 hours in adults with normal renal function; prolonged to 7-21 hours in hepatic impairment; no significant change in renal impairment; clinically relevant for dosing interval (usually 8-hourly).
7-8 hours in healthy adults; prolonged to 20-30 hours in severe hepatic impairment.
Renal: 60-80% of dose excreted unchanged in urine; biliary/fecal: 6-15% as metabolites and unchanged drug; enterohepatic circulation contributes to prolonged elimination.
Renal 60-80% as unchanged drug and metabolites; fecal 6-15%; biliary minor.
Category C
Category A/B
Nitroimidazole Antibiotic
Nitroimidazole Antibiotic